Market news

Summit Therapeutics stock jumped Tuesday on AstraZeneca's investment.

While Pfizer's dividend looks like a trap, its strong balance sheet and low valuation make it safer.

Milestone reflects continued progress in collaboration to develop a novel class of degrader antibody conjugates, or DACsBRISBANE, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced the achievement of a $7 million research milestone under its strategic collaboration with Pfizer for the discovery and devel

How Pfizer, Lumen, Cisco, UPS, Palo Alto Networks, and Thermo Fisher are moving AI beyond pilots—using it to reshape drug discovery, networks, logistics, cybersecurity, and daily work.

Pfizer has a compelling risk-reward profile despite near-term COVID normalization and patent expiry headwinds. Find out why PFE stock is a Buy.

Delaware judge lets Monsanto’s mRNA patent lawsuits vs Pfizer, BioNTech, and Moderna proceed. Read more here.

Pfizer (NYSE:PFE) is set to feature data from 45 oncology research abstracts at the upcoming ESMO Congress. The company plans multiple oral presentations on late-stage cancer candidates alongside results for established oncology medicines. New clinical readouts at ESMO will spotlight Pfizer's late-stage oncology pipeline and marketed cancer drugs, against a broader backdrop our research has surfaced. Take a look at 4 warning signs we have identified for Pfizer. For investors tracking how...

Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Pfizer (NYSE:PFE) released second-quarter financial results and hosted an earnings call on Tuesday. Read the complete transcript below. Benzinga APIs provide real-time access to earnings call transcripts and financial

NEW YORK, September 28, 2026--Pfizer Inc. (NYSE: PFE) will present data from 45 company-sponsored, investigator-sponsored, and collaborative research abstracts at the European Society for Medical Oncology (ESMO) Congress, taking place October 23-27, 2026 in Madrid, Spain. The presentations include 11 oral presentations spanning Pfizer’s established medicines and late-stage pipeline across its disease areas of focus, including breast cancer, genitourinary cancers, and lung cancer.

Pfizer Inc. (NYSE:PFE) and Gilead Sciences, Inc. (NASDAQ:GILD) present investors with two very different forms of concentration risk. Pfizer needs newer medicines and its pipeline to offset revenue that will increasingly face generic and biosimilar competition, while Gilead has the opposite problem, where its biggest franchise is performing extremely well, but HIV accounts for roughly […]

Pfizer Inc. (NYSE:PFE) and Medtronic plc (NYSE:MDT) are both trying to prove that years of portfolio investment can translate into more durable growth, but the two healthcare giants are entering very different stages of their turnarounds. Pfizer is rebuilding around newer medicines as COVID revenue declines and generic and biosimilar competition approaches. Medtronic, meanwhile, is […]

Pfizer Inc. (NYSE:PFE) and Thermo Fisher Scientific Inc. (NYSE:TMO) are both trying to put difficult post-pandemic periods behind them, but their recoveries look very different. Thermo Fisher is benefiting from improving activity across life-sciences markets after a prolonged slowdown in pharmaceutical and biotech spending. Pfizer, meanwhile, is trying to rebuild growth around newer medicines as […]

Pfizer Inc. (NYSE:PFE) has agreed to share a portion of the incremental net revenue it generates from higher drug prices overseas with the U.S. Department of Health and Human Services (HHS), according to newly released documents covering its Most Favored Nation (MFN) pricing agreement. The provision applies to medicines already on the market and runs […]

Pfizer's post pandemic earnings quality does not warrant a peer multiple, and from five consecutive years of decline. Learn why PFE stock is a buy.

On September 13, 2026, the Wall Street Journal reported that Pfizer Inc. (NYSE:PFE) is enforcing a Belgian court judgment against Poland and Romania over unpaid COVID-19 vaccine orders by targeting an unusual source of leverage: air traffic control fees. Eurocontrol, the intergovernmental body that coordinates European air traffic management, has frozen transfers of airline route […]

AbbVie pivots toward newer immunology drugs while Pfizer leans on acquisitions to offset pandemic decline, but their financial profiles and valuations tell starkly different stories.

The pharmaceutical giant sent shareholders a torrent of cash, yet the stock itself went backward. Here is the accounting of what owners actually received.

Pfizer (NYSE:PFE) is focusing more of its research pipeline on therapies eligible for FDA Breakthrough Therapy and orphan drug status. The FDA has widened use of Breakthrough Therapy designations in areas such as oncology, which can shorten review and approval timelines. Global orphan drug markets are expanding in value as genomics, faster approvals, and government incentives support treatments for rare diseases. The growing role of Breakthrough Therapy labels and orphan drugs for Pfizer is...

Pfizer Inc. (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) announced on August 27 that the U.S. FDA has approved the supplemental Biologics License Application for their 2026–2027 COVID-19 vaccine formula, COMIRNATY XFG. The updated formula targets the XFG variant and is authorized for adults aged 65 and older, as well as individuals aged 5 to 64 with […]

Pfizer faces some major LoE headwinds, but the stock is cheap and offers a large dividend, offering a solid total return potential. Click to read more on PFE.

AbbVie and Pfizer are reshaping their growth strategies as new drugs, acquisitions, pipelines and patent challenges shape their outlooks.

Pfizer's COVID products keep shrinking. The company's total revenue has been flat for a year. That makes the best case for this stock easy to miss. It does not rest on the medicines you already know Pfizer (PFE) for. It is not another round of cost cuts either. It rests on a smaller and faster part of the company. So where is that growth coming from.

Lilly and Pfizer both reported recent quarters that turned heads for opposite reasons, and heading into 2027 only one of them deserves your pharmaceutical capital. The answer depends on a trade-off most investors get wrong.

Key Stats for Pfizer StockCurrent Price: $27. 93Target Price (Mid): ~$29Street Target: ~$29Potential Total Return: ~5%Annualized IRR: ~1.

BridgeBio (BBIO) says heart disease therapy Attruby beat Pfizer’s (PFE) rival drug, tafamidis, branded as Vyndamax, in a real-world study. Read more here.

Pfizer has quietly put together a 23.9% gain over the past year, and that kind of move invites a closer look at whether the current share price lines up with what its earnings can support. With the stock recently closing at US$27.93, the question is how much of the latest news and revenue mix shifts are already reflected in that figure. The 23.9% 1 year return has reset expectations for Pfizer, which puts more weight on whether its earnings base can carry that higher price level. Fresh...

These are among the highest-yielding stocks on the S&P 500.

Pfizer delivered a Q2 double beat, raised full-year revenue guidance, and benefits from pipeline progress. Read why PFE stock is a Buy.

When investing in a dividend stock, it's important to consider not just the yield, but also the potential for dividend growth and overall risk.

Pfizer outlook: acquired products drive 21% of revenue (+18% YoY); Metsera GLP-1 pipeline could reignite growth post-2028. Click for more on PFE stock.

Here's why they made the list

Public Citizen exposes separate government drug deals with Pfizer and Eli Lilly, warning the pacts could increase global drug prices.

Pfizer (NYSE:PFE) has rebuilt its commercial model around newer and acquired products while reducing exposure to its COVID-19 franchise, according to Alexandre de Germay, the company’s chief international commercial officer and executive vice president. Speaking with Chris Schott at a company event

Pfizer Reveals Surprise HHS Revenue-Sharing Terms in Overseas Drug Pricing Deal

Pfizer (PFE) has returned 23.1% over the past year and trades about 5% below its three-year high. Yet one question keeps coming back on its earnings calls: would it ever cut the dividend? An analyst asked it outright on the August call, and another tied it to a big acquisition in May. So what would a cut take, and what would it change.

Pfizer may share revenue with HHS if it raises drug prices abroad under a “most favored nation” contract for 2026–2029.

Pfizer's rebound is well underway.

Pfizer has a history of developing treatments that generate billions in sales.

Pfizer (PFE) heads into its Morgan Stanley Global Healthcare Conference presentation on 14 September with investors watching how management frames dividend priorities, recent pipeline setbacks, and the evolving role of newer oncology partnerships. At a share price of US$27.64, Pfizer has logged a 9.8% year to date share price return and a 22.5% total shareholder return over the past 12 months. This represents a rebound that has built momentum over the last three months as dividend messaging,...